Please Wait.....
Report
United States Prostate Cancer Testing Market By Biomarker Type (Pre-Biopsy/Post-Negative Biopsy Testing, Initial Evaluation: Prostate-Specific Antigen (Total PSA, Free PSA), Post-Biopsy Tissue Testing), By Application (Diagnostics Biomarkers, Prognostics Biomarkers), By End User (Cancer Research Institutes, Diagnostic Laboratories, Hospitals and Clinics, Ambulatory Surgical Center (ASCs), and Others), By Region, Competition Forecast & Opportunities, 2018-2028
Market Report I 2023-07-01 I 78 Pages I TechSci Research
United States Prostate Cancer Testing Market is expected to grow at an impressive rate during the forecast period 2024-2028. The major factors include the increasing prevalence of prostate cancer in men, increasing prostate cancer screening and testing, early diagnosis of prostate cancer, and increasing interest of the government in cancer testing and medical advancement. According to Global Cancer Observatory, in 2020, around 2281,658 new cancer cases were reported in the United States, among which 209,512 cases reported were of prostate cancer. Additionally, increasing awareness among the public for early prostate diagnosis and detection is further expected to drive the growth of United States prostate cancer testing market.
The prostate gland's aberrant cells multiply and uncontrollably enlarge in men with prostate cancer. The tenth leading cause of mortality overall and the sixth major cause of death in men is prostate cancer. According to Statista, the United States leads among all countries across the globe in terms of spending on research and development, with expenditures exceeding USD679.4 billion.
Rising prevalence of prostate cancer
In United States, prostate cancer is the most prevalent cancer in men. This is diagnosed in about 6 out of 10 men who are 65 years old and rare in men under 40 years. Prostate cancer is the second most common cancer among American males, after lung cancer. For instance, in the United States, it was predicted that about 268,490 new cases of prostate cancer were reported in 2022, up from 192,280 new cases in 2009. Moreover, it was estimated that in 2022 around 34,500 men will die of prostate cancer in the U.S.
Growing Geriatric Population
Globally, cancer is the leading cause of death. According to the American Society of Clinical Oncologists, prostate cancer is more than twice as likely in people over 70 years as compared to younger people. This is due to genetic disorders, unhealthy lifestyles, environment, radiation, physical carcinogens, chemical carcinogens as well as biological carcinogens. The need to develop testing procedures for cancer is expected to support the growth of the US prostate cancer testing market.
Government Initiatives Related to Prostate Cancer
The government provides funding for developing new technologies to enhance the testing of prostate cancer positively. For instance, the National Cancer Institute initiated Prostate Specialized Programs of Research Excellence (SPORE), -a program designed to convert scientific findings into clinical settings-based outcomes. The institute also facilitates the development of new technologies and studies to gain a better understanding of monitoring, prevention, diagnosis, and treatment. Such initiatives are expected to drive the growth of the United States Prostate Cancer Testing Market.
Technological Development
The techniques like prostate-specific antigen (PSA) testing, which have developed over the years that confirm tumor progression and proliferation, have created new prospects for the growth of prostate cancer testing over the years. Moreover, prostate cancer testing is essential in precision medicine because it assures the safe and successful use of testing methods. Additionally, most of the companies in the U.S. prostate cancer testing market provide biomarker tests that are urine, blood, and tissue-based, as well as testing services. This, in turn, shows an impressive rate of growth in the United States prostate cancer market.
Recent Developments
According to the Journal of the National Cancer Institute, in September 2022, a company, namely Veracyte, Inc., announced the publishing of data to demonstrate that the company's decipher prostate genomic classifier may help identify African American men with early, localized prostate cancer who are most likely to harbor more aggressive disease.
Additionally, in June 2021, Thermo Fisher Scientific announced submissions open for the Oncomine Clinical Research Grant program to support clinical research projects in oncology. Due to this grant, the funding for high-quality molecular profiling studies focuses on the impact of immune-based treatments for cancer patients.
Market Segmentation
United States Prostate Cancer Testing Market can be segmented by biomarker type, application, end-user, region, and competitive landscape. Based on biomarker type, the market can be segmented into pre-biopsy/post-negative biopsy testing, initial evaluation: prostate-specific antigen (Total PSA, Free PSA), and post-biopsy tissue testing. Based on application, the market can be segmented into diagnostics biomarkers and prognostics biomarkers. In terms of end users, the market can be segmented into cancer research institutes, diagnostic laboratories, hospitals and clinics, ambulatory surgical centers (ASCs), and others.
Market Players
F. Hoffmann-La Roche Ltd (Foundation Medicine, Inc.), Siemens Healthcare GmbH, OPKO Health, Inc. (GenPath), Myriad Genetics Inc., NeoGenomics Laboratories, Danaher. (Beckman Coulter, Inc.), Agilent Technologies, Inc., Abcam plc., Bio-Techne. (ExoDx), H.U. Group Holdings, Inc. (Fujeribio), etc., are some of the leading companies operating in the market.
Report Scope:
In this report, United States Prostate Cancer Testing Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
- United States Prostate Cancer Testing Market, By Biomarker Type
o Pre-Biopsy/Post-Negative Biopsy Testing
o Initial Evaluation: Prostate-Specific Antigen (Total PSA, Free PSA)
o Post-Biopsy Tissue Testing
- United States Prostate Cancer Testing Market, By Application
o )
o Diagnostics Biomarkers
o Prognostics Biomarkers
- United States Prostate Cancer Testing Market, By End User
o Cancer Research Institutes
o Diagnostic Laboratories
o Hospitals and Clinics
o Ambulatory Surgical Centers (ASCs)
o Others
- United States Prostate Cancer Testing Market, By Region:
o Northeast
o Midwest
o South
o West
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in United States Prostate Cancer Testing Market
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. 1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. United States Prostate Cancer Testing Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Biomarker Type (Pre-Biopsy/Post-Negative Biopsy Testing, Initial Evaluation: Prostate-Specific Antigen (Total PSA, Free PSA), Post-Biopsy Tissue Testing)
5.2.2. By Application (Diagnostics Biomarkers, Prognostics Biomarkers)
5.2.3. By End User (Cancer Research Institutes, Diagnostic Laboratories, Hospitals and Clinics, Ambulatory Surgical Center (ASCs), and Others)
5.2.4. By Region (Northeast Region, Midwest Region, South Region, West Region)
5.2.5. By Company (2022)
5.3. Market Map
5.3.1. By Biomarker Type
5.3.2. By Application
5.3.3. By End User
5.3.4. By Region
6. Northeast United States Prostate Cancer Testing Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Biomarker Type
6.2.2. By Application
6.2.3. By End User
7. Midwest United States Prostate Cancer Testing Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Biomarker Type
7.2.2. By Application
7.2.3. By End User
8. South United States Prostate Cancer Testing Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Biomarker Type
8.2.2. By Application
8.2.3. By End User
9. West United States Prostate Cancer Testing Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Biomarker Type
9.2.2. By Application
9.2.3. By End User
10. Market Dynamics
10.1. Drivers
10.1.1. Rising prevalence of prostate cancer
10.1.2. Growing geriatric population
10.1.3. Government Initiatives related to Prostate Cancer
10.1.4. Technological Advancement
10.1.5. Recent Development
10.2. Challenges
10.2.1. High Probability of False Positives during Prostate Cancer Testing
11. Market Trends & Developments
12. United States Economic Profile
13. Competitive Landscape
13.1. Business Overview
13.2. Product Offerings
13.3. Recent Developments
13.4. Financials (As Reported)
13.5. Key Personnel
13.5.1. F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.).
13.5.2. Siemens Healthcare GmbH
13.5.3. OPKO Health, Inc. (GenPath)
13.5.4. Myriad Genetics Inc.
13.5.5. NeoGenomics Laboratories
13.5.6. Danaher. (Beckman Coulter, Inc.)
13.5.7. Agilent Technologies, Inc.
13.5.8. Abcam plc.
13.5.9. Bio-Techne. (ExoDx)
13.5.10. H.U. Group Holdings, Inc. (Fujeribio)
14. Strategic Recommendations
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security